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A B S T R A C T
Rubinstein-Taybi syndrome (RSTS) is a rare neurodevelopmental disorder characterized by distinctive facial
features, growth retardation, broad thumbs and toes and mild to severe intellectual disability, caused by het-
erozygous mutations in either CREBBP or EP300 genes, encoding the homologous CBP and p300 lysine-acet-
yltransferases and transcriptional coactivators. No RSTS in vitro induced Pluripotent Stem Cell (iPSC)-neuronal
model is available yet to achieve mechanistic insights on cognitive impairment of RSTS patients. We established
iPSC-derived neurons (i-neurons) from peripheral blood cells of three CREBBP- and two EP300-mutated patients
displaying diﬀerent levels of intellectual disability, and four unaﬀected controls. Pan neuronal and cortical-
speciﬁc markers were expressed by all patients' i-neurons. Altered morphology of patients' diﬀerentiating neu-
rons, showing reduced branch length and increased branch number, and hypoexcitability of diﬀerentiated
neurons emerged as potential disease biomarkers. Anomalous neuronal morphology and reduced excitability
varied across diﬀerent RSTS patients' i-neurons. Further studies are needed to validate these markers and assess
whether they reﬂect cognitive and behavioural impairment of the donor patients.
1. Introduction
Rubinstein-Taybi syndrome (RSTS1 MIM 180849, RSTS2 MIM
613684) is a very rare (1: 125.000) autosomal dominant disorder
characterized by distinctive facial dysmorphisms (mainly downslanting
palpebral ﬁssures, broad nasal bridge/beaked nose, columella below
the alae nasi, microcephaly) skeletal anomalies, including the diag-
nostic sign of broad/short thumbs and/or big toes, mild-to-severe in-
tellectual disability (ID), multiple organ anomalies and increased
cancer risk (Hennekam, 2006). Heterozygous de novo mutations in ei-
ther of the two highly conserved CREBBP or EP300 genes, encoding the
CBP and p300 histone and non-histone lysine acetyltransferases, acting
in chromatin remodelling and transcriptional activation, account for
55% and 8% of clinically diagnosed patients, respectively (Spena et al.,
2015; Negri et al., 2016). Like other developmental disorders with in-
tellectual disability (DD/ID) caused by genes of the “epigenetic ma-
chinery” (Bjornsson, 2015) RSTS is characterized by wide phenotypic
breadth, although the clinical presentation including cognitive im-
pairment is globally milder in RSTS2 than in RSTS1 patients (Negri
et al., 2016; Fergelot et al., 2016). Besides the aﬀected locus, the site
and type of mutation are strong determinants of the variable overall
phenotype and intellectual disability which represents the most
common and handicapping sign across and within CREBBP and EP300-
mutated patients. Most pathogenic variants in both causative genes are
inactivating (frameshift, nonsense, splice-site) and are predicted to
exert their eﬀect by a loss of function mechanism leading to
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haploinsuﬃciency, though dominant negative inhibition of wild type
allele by putative truncating variants has been also proposed (Park
et al., 2014). As regards missense variants, rare in EP300, those mainly
clustered in CREBBP exons encoding the lysine (K) acetyltransferase
(KAT) domain, are shown to encode proteins defective in the key cat-
alytic function. Conversely a gain of function mechanism has been
hypothesized for missense mutations in parts of CREBBP exons 31–32
and homologous EP300 regions aﬀecting the proper conformation of
zinc ﬁngers domains. Patients carrying these variants manifest a phe-
notype distinct from the classic one (Menke et al., 2018), consistent
with the huge RSTS phenotypic variability.
Notwithstanding the generation of patient-speciﬁc iPSCs neurons
has been an increasingly used tool to dissect the etiology of neurode-
velopmental disorders (Chamberlain, 2016; Ardhanareeswaran et al.,
2017), no iPSC modeling has been developed for RSTS to date. We
selected from our wide cohort of molecularly characterized CREBBP-
and EP300-mutated patients cases representative of diﬀerent levels of
intellectual impairment to generate, along with unaﬀected controls,
iPSCs-derived neurons. We herein present data on the successful re-
programming to iPSCs of blood cells of four RSTS1 and two RSTS2 cases
and the obtainment of neuronal derivatives in all cases. Characteriza-
tion of i-neurons from ﬁve patients shows that RSTS i-neurons display,
by cellular morphology and electrophysiology, a number of diﬀerences,
as compared to controls, which attest impairment, variable across pa-
tients, of the proper diﬀerentiation program.
2. Materials and methods
2.1. Ethic issues
This study was approved by the Institutional ethical committee of
IRCCS Istituto Auxologico Italiano, Milan. Written informed consent
was obtained from all patients' parents and control individuals.
2.2. Selection of RSTS patients for iPSC reprogramming
Six patients were selected for iPSC modeling based on their avail-
ability for the study from previously clinically and molecularly char-
acterized RSTS1 and RSTS2 patients and named with their original code
(#34, #46, #149, #158 and #65, #207). The clinical description and
molecular characterization of CREBBP-mutated patients #34, #46,
#149 and #158 can be found in Bentivegna et al., 2006, Lopez-Atalaya
et al., 2012 and Spena et al., 2015, and of EP300-mutated patients #65
and #207 in Negri et al., 2016.
Four control individuals were selected for iPSCs reprogramming. C1
and C2 are adult healthy females aged 51 and 40 at the time of with-
drawal: C2 is the mother of patient #149. C3 and C4 are pediatric
controls, aged 16 and 4 at the time of withdrawal: C3 is the healthy
brother of patient #34 and C4 is the healthy sister of a patient aﬀected
by Angelman syndrome.
2.3. Neuropsychiatric assessment of RSTS patients
To assess Intellectual Quotient (IQ) the Leiter International
Performance Scales Revised – Leiter-R (age range 2–21) was used (Roid
and Miller, 1997), for its nonverbal characteristics and the availability
of a brief form. A brief IQ in fact can be obtained, even if the patients
show signiﬁcant attention and communication diﬃculties. To assess the
General Quotient of Development (GQ) the Griﬃths' scale (Griﬃths,
1986) which gives a GQ in patients from 0 to 8 years old, was used.
The behavioural characteristics of the patients were assessed using
the Child Behaviour Checklist-CBCL 1.5–5 and 6–18 forms (Achenbach
and Rescorla, 2001). The CBCL is a questionnaire about the behavioural
characteristics of the child ﬁlled in by the parents. Each item is rated
from 0 to 2. Internalizing, Total and Externalizing problems scales and
6 DSM IV oriented scales are obtained by the items score. We used the
Social Communication Questionnaire: Lifetime Version SCQ (Rutter
et al., 2003; Berument et al., 1999) to assess Autism spectrum disorders
(ASD). The SCQ is a 40 item informant screening questionnaire for the
presence of ASD in people with IDs. The SCQ was shown to have good
concurrent validity with the Autism Diagnostic Observation Schedule
(ADOS) and Autism Diagnostic Interview (ADI) (Berument et al., 1999;
Howlin and Karpf, 2004).
2.4. Generation and culture of iPSCs
iPSCs were generated from Peripheral Blood Mononuclear Cells
(PBMCs) of RSTS patients and healthy controls as described (Dowey
et al., 2012). Cells were transduced with integration-free Sendai virus
kit (CytoTune 2.0,Thermo Fisher Scientiﬁc Waltham, MA, USA) and
grown on MEF (Mouse Embryonic Fibroblast) feeder layer in human
embryonic stem cell medium (DMEM-F12, 20% knockout serum re-
placement, 1 mM L-glutamine, 1× nonessential amino acids, 100mM β-
mercaptoethanol), supplemented with 4 ng/ml of basic ﬁbroblast
growth factor (all reagents from Thermo Fisher). Cells were manually
passaged weekly. Single iPSC colonies were cut using a syringe needle
and the pieces transferred to new feeder coated wells.
2.5. Karyotyping and a-CGH of iPSC clones
The cytogenetic analysis was performed using QFQ-banding tech-
niques on metaphase chromosomes obtained by standard procedures
from peripheral blood lymphocytes and from iPSC clones at passages
from P4 to P8. At least 30 metaphases were scored in each case.
Genomic blood DNA was extracted by the means of GenElute Blood
Genomic DNA kit (Sigma-Aldrich, St. Louis, MO, USA); iPSC genomic
DNA was extracted from iPSC clones (P4-P8) by Wizard Genomic DNA
Puriﬁcation Kit (Promega, Madison, WI, USA).
High-resolution array comparative genomic hybridisation (array-
CGH) was performed on genomic blood and iPSC DNA using the
SurePrint G3 Human CGH Microarray Kit 2x400K and 4x180K in ac-
cordance with the manufacturer's instructions (Agilent Technologies,
Palo Alto, CA,USA). Probe positions are referred to human genome
assembly GRCh37/hg19.
2.6. Characterization of genetic defects in iPSC cell lines
Genomic DNAs from iPSC clones controlled for genomic stability
were subjected to bi-directional Sanger sequencing (Applied
Biosystems, Carlsbad, CA, USA) to disclose the original CREBBP or
EP300 mutation, as described (Bentivegna et al., 2006; Spena et al.,
2015; Negri et al., 2016).
Transcript analysis was performed using the primers previously
employed on lymphoblastoid cell line/peripheral blood from CREBBP-
mutated patient #46 (Lopez-Atalaya et al., 2012) and EP300-mutated
patients #65 and #207 (Negri et al., 2016). New primers pairs were
designed for CREBBP-mutated patients #149 (c.CREBBP_Ex17F
5′-TACGCCAGGCCCTCATG-3′/c.CREBBP_Ex19-20R 5′-CAGAAATGATA
CCTATTCTG-3′) and #158, (c.CREBBP_Ex26F 5′-TACCATGAGATCCTT
ATTGGAT-3′/c.CREBBP_Ex29-30R 5′-AGAAGACCTCCTTGTGCT-3′),
while the primer pair designed for #46, was also used to detect tran-
scripts of patient #34 iPSCs.
2.7. Western blot
iPS cell extracts (120 μg) were separated on NuPAGE 4–12% Bis-Tris
Gel (Invitrogen, Waltham, MA, USA), transferred to nitrocellulose and
blocked with 5% BSA in PBS-0.2% Tween 20 (PBS-T). The membrane
was incubated for 1 h at RT with rabbit polyclonal anti CBP (A-22) (sc-
369)1:300 or rabbit polyclonal anti p300 (N-15) (sc-584) 1:300 (both
Santa Cruz, Dallas, TX, USA) and anti-actin mouse monoclonal 1:2.000
(Sigma-Aldrich, St Louis, MO, USA) followed by washings in PBS-T and
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incubation for 30min at RT in HRP-labeled secondary anti-rabbit and
anti-mouse antibodies 1: 2.000 (Thermo Fisher Scientiﬁc).
Chemiluminescence signals were revealed with a Westar R imager (Hi-
Tech Cyanagen, Bologna, Italy).
2.8. In vitro diﬀerentiation of iPSCs to cortical neurons
Clones which bypassed the check for genome stability were diﬀer-
entiated into cortical neurons according to the monolayer protocol in
N2B27 medium (Neurobasal medium, 2% B27, 1% Insulin Transferrin
Selenium, 1% N2, 2mM L-Glutammine, 0.5% P/S) (all reagents from
Thermo Fisher Scientiﬁc, Waltham, MA, USA) supplemented with
500 ng/ml Noggin (R&D Systems, Minneapolis, MN, USA) (Germain
et al., 2014). Once, usually after 14–16 days, neural rosettes appeared,
they were manually passaged on poly ornithine-laminin (Sigma-Al-
drich, St Louis, MO USA) coated dishes and maintained in the same
medium for further two weeks. At day 28 the N2B27 medium was
changed to Neural Diﬀerentiation Medium (Neurobasal medium, 2%
B27, 1% NEAA, 2mM L-Glutammine) (all reagents from Thermo
Fisher), plus 10 ng/ml BDNF, 10 ng/ml GDNF (both from Peprotech,
London, UK), 1 μM Ascorbic Acid and 200 μM cAMP (both from Sigma-
Aldrich). After one week neural progenitor cells (NPCs) were plated at
low density (1× 105–1.5×105 cells in a 9.6 cm2 well) for terminal
diﬀerentiation and not passaged any more. NPCs could be frozen and
thawed without loss of potency. Neurons were maintained in culture by
half media changes twice a week until 70 or 100 days.
2.9. Immunoﬂuorescence staining
Cells were ﬁxed in 4% paraformaldehyde for 20min at 37 °C.
Primary antibodies were applied at 4 °C overnight. Secondary anti-
bodies were incubated with cells for 2 h at room temperature. The
following antibodies were used: Oct3/4 (sc-9081)1:200, Tra-1-60 (sc-
21705) 1:100, CUX-1 (sc-13,024) 1:100 (Santa Cruz Biotechnology,
Dallas, TX, USA); Nestin (ab22035) 1:300, Map2 (ab32454) 1:300,
TBR1 (ab31940)1:200, Synaptophysin (ab14692) 1:200 (Abcam,
Cambridge, UK); TUJ1 (801201) 1:500, Pax6 (PRB-278P) 1:300
(Covance Princeton, NJ, USA); Anti-GAD 65/67 (AB1511) 1:100; Anti
V-GLUT1 (MAB5502) 1:100 (Millipore Burlington, MA, USA); Goat anti
mouse Alexa ﬂuor 488 (1:500), Goat anti rabbit Alexa ﬂuor 555 (1:300)
(Thermo Fisher). DAPI was used to counterstain cell nuclei. Bright ﬁeld
images were acquired with JuLITM cell analyzer (10–20× digital
zoom). Confocal images of 1024×1024 pixels were obtained with
Nikon Eclipse Ti microscope.
2.10. RT-PCR
Total RNA was isolated from iPSCs using Trizol reagent and 1 μg
was retro-transcribed using SuperScript Vilo (Thermo Fisher) according
to manufacturer's instructions. cDNAs were ampliﬁed using GoTaq
(Promega, Madison, WI, USA).The following primers (designed by Dr.
V. Silani's group, Milano) were used to amplify Nanog: forward CAGC
CCTGATTCTTCCACCAGTCC and reverse GTTCTGGAACCAGGTCTTCA
CCTG. The ampliﬁcation of OCT3/4 and SOX2 genes was performed
using primers reported by the Yamanaka's group (Takahashi et al.,
2007).
2.11. Morphological characterization of neural progenitors
Morphological analysis of branches (average branch length and
average branch number) was performed on 42–day-old neurons stained
for TUJ1. All 1024×1024 pixels images were acquired with Nikon
Eclipse Ti confocal microscope and 40× objective. 30–50 cells were
selected for every sample and analyzed by the ImageJ plugin Analyze
Skeleton (Arganda-Carreras et al., 2010).
2.12. Electrophysiology recordings of diﬀerentiated neurons
Whole-cell patch-clamp recordings were performed on 70-day-old
diﬀerentiated neurons at room temperature (∼25 °C) using a
Table 1
Patients selected for iPSCs: age, aﬀected locus, type of mutation and predicted eﬀect on protein, neuropsychological assessment at reprogramming, main clinical
features and references on previous clinical and molecular characterization.
Patient
code sex
age (y)
Gene Mutation site and
predicted eﬀect on
protein
RSTS
dysmorphisms
Growth
retardation
Neuropsychiatric
Assessment
Skeletal anomalies Organ
malformation
Cancer
development
References
IQ*/GQ° Behavioural
proﬁle #
Broad
thumbs
Broad
halluces
CREBBP
NM_004380
34 M
(12)
Exon 27 c.4435G>T + + 47* Normal + − − − Bentivegna
et al., 2006p.(Gly1479*)
46 F
(13)
Exon 28 c.4627G>T + + 61* Behavior
disorder
+ + Renal hypoplasia Multiple
pilomatricoma
Bentivegna
et al., 2006p.(Asp1543Tyr)
Lopez-
Atalaya
et al., 2012
149 M
(6)
Exon 18 c.3474G>A + + 25° ASD + − Cerebellar
hypoplasia,
corpus callosum
agenesis,
cryptorchism, feet
polidactyly
− Spena et al.,
2015p.(Trp1158*)
158 F
(5)
Exon 28 c.4650-4654del + + 45° Normal + − PDA, pulmonary
valve stenosis
Hepatoblastoma Spena et al.,
2015p.(Glu1551Hisfs*2)
Milani, 2016
EP300
NM_001429
65 M
(25)
Exon 23 c.3829A>T + + “Mild” ADHD + + − Multiple naevi Negri et al.,
2016p.(Lys1277*)
207 M
(19)
IVS 9 c.1878-12A>G + + 42* behavior
disorder
+ + − − Negri et al.,
2016p.(Ala627Glnfs*11)
*Assessed by Leiter R (*) or Griﬃth's scale (°), assessed by CBCL, SCQ (#).
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Multiclamp 700A ampliﬁer and pClamp 10.5 software (Molecular
Devices, Sunnyvale, CA, USA) in voltage- or current-clamp conﬁgura-
tion, as in Verpelli et al., 2013 and Terragni et al., 2016. Signals were
ﬁltered at 10kHz and sampled at 200kHz for voltage-clamp recordings
or 20 kHz for current-clamp recordings. External bath solution con-
tained (mM): 129NaCl, 1.25NaH2PO4, 35glucose, 1.8 MgSO4, 1.6
CaCl2, 3KCl and 10 HEPES, pH 7.4 with NaOH. The internal pipette
solution contained (mM): 120 K-gluconate, 15 KCl, 2 MgCl2, 0.2 EGTA,
10HEPES, 20 phosphocreatine-tris, 2 ATP-Na2, 0.2mM GTP-Na2 and
0.1 leupeptin, pH 7.2 with KOH. Pipette resistance was between 3 and
4MΩ. Cell capacitance and series resistance errors were carefully
compensated (∼85%) throughout the experiment. The remaining
linear capacity and leakage currents were eliminated online using a P/4
subtraction paradigm. Total voltage-gated currents were elicited by
applying 66ms-long depolarizing voltage steps from −70 to +60mV
(10mV increments), from a holding potential of −70mV. Sodium and
potassium current densities were obtained by dividing the recorded
currents for the cell capacitance, measured by integrating the capaci-
tative current evoked by a 10mV hyperpolarizing voltage step from the
holding potential. Discharges of action potentials (APs) were evoked by
the injection of 2.5 s-long depolarizing current pulses of increasing
amplitude from the resting potential maintained at−70mV. The input-
output relationship is the plot of the number of APs generated vs. the
amplitude of the injected current. Rheobase was deﬁned as the minimal
current amplitude needed to reach the threshold for action potentials.
AP threshold was calculated with the ﬁrst derivative method.
2.13. Statistical analyses
Morphological characterization: diﬀerences in number and average
length of neural progenitors branches were evaluated by a Kruskal-
Wallis test followed by Dunn's Multiple comparison test with
Bonferroni's correction. Correlation analysis of these two features was
performed by using Spearman's rank correlation. Analyses were con-
ducted in R environment by using speciﬁc packages. Graphics (box-
plots and scatter-plots) were generated through GraphPad Prism (V.7)
software.
For electrophysiological experiments, graphics and statistical ana-
lysis were obtained using pClamp and Origin 8 software. Proportions
(percentages of neurons with sodium current or generation of APs) were
analyzed with Fisher's exact test. Data on sodium and potassium current
densities, input-output relationship, membrane capacitance, rheobase
and AP threshold are given as mean ± SEM and were analyzed with
ANOVA and Bonferroni post-test.
Statistical signiﬁcance was set at p= 0.05
The workﬂow of iPSC generation and characterization is outlined in
Suppl. Fig. 1.
3. Results
3.1. Neuropsychiatric assessment of RSTS- patients selected for iPSC
generation
“Ad hoc” neuropsychiatric assessment, including Intellectual
Quotient (IQ) or General Quotient of Development (GQ) according to
patient age and behavioural characteristics was performed by the same
neuropsychiatrist (P.F.A.) in parallel to iPSCs generation (patients #34,
#46, #149 and #207). Updated evaluation was obtained by contact
with the local neuropsychiatrist for patients #65 and #158. Table 1
provides for the six patients the age at withdrawal for iPSC generation,
the aﬀected CREBBP or EP300 locus, the location and type of patho-
genic variant and predicted eﬀect on the protein, the assessed score of
intellectual level plus the presence/absence of behaviour disorder and
the main RSTS clinical features. These are detailed together with the
molecular characterization in the attached references. Out of the four
CREBBP-mutated patients, a mild ID (intellectual disability according to
Fig. 1. Immunoﬂuorescence and morphological characterization of iPSC-de-
rived neural progenitors and early neurons. A) Left: bright-ﬁeld images of
neural rosettes (10×) from C1, C4, #34cl7, #46, #158, #65 and #207. Right:
immunoﬂuorescence positive staining of the neuroectodermal stem cell markers
NESTIN and PAX6 on coverslips from C1, C2, #34cl7, #46, #158, #65 and
#207. Scale bar 50 μm. B) Immunostaining of 42-day-old neurons from the
same controls and patients showing positivity for the pan neuronal cell markers
MAP2 and TUJ1. Nuclei are counterstained with DAPI. Scale Bar 50 μm.
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ICD 10 classiﬁcation) is assigned to #46 carrying a missense mutation
in the KAT domain, while patients #149, #34 and #158 carrying in-
activating mutations predicted to lead either to haploinsuﬃciency or to
truncated proteins lacking all or part of KAT and downstream domains,
have in the order a severe or moderate ID according to IQ/GQ scores.
Based on parents' point of view clinical scores of ASD are present in
patient #149 who is placed at the most severe end of the ID spectrum of
this RSTS cohort. Behavioural disorder is not observed for patients #34
and #158, while high social anxiety, diﬃculties in peer-relationship
and withdrawn behaviours are recorded for the best performing
CREBBP-mutated patient #46.
As to the two adult EP300-mutated patients, #65 carrying a non
sense mutation predicting a protein, if any, lacking the KAT and
downstream domains, has deﬁnitely a mild ID (he achieved a diploma
in social sciences) and only suﬀered from attention deﬁcit hyperactivity
disorder, while #207 carrying an IVS9 variant yielding a cryptic ac-
ceptor splice site and out-of-frame transcript predicting early protein
truncation combines a moderate ID with a severe behavioural disorder
(Negri et al., 2016).
3.2. Generation and characterization of RSTS-speciﬁc iPSCs
iPSCs were generated from PBMCs of the above listed RSTS patients
and four control subjects using the Sendai virus (SeV) non integrative
Fig. 2. Immunoﬂuorescence characterization of cortical markers in patient-speciﬁc 70 days i-neurons. A) Positive immunostaining of TUJ1 and the early cortical
marker TBR-1 in C3, #34cl2, #158, #65 and #207 neurons. B) Representative pictures of C4, CREBBP-mutated #34cl2, #46 and EP300-mutated #65 and #207
neurons showing the positive immunostaining of TUJ1 and the post-mitotic cortical neurons marker CUX-1. C) Positive immunostaining of synaptophisyn (SYP) and
TUJ1 in neurons from C4, 34cl2, #46 and #65. The insets show a 4× magniﬁcation view of framed ﬁelds of merge images of immunolabeled cells.
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reprogramming method which is currently mostly used for its eﬃ-
ciency, safety and simple handling (Soares et al., 2016). Two controls,
C2 and C3, mother and brother of patients #149 and #34, respectively,
fulﬁl the family design, allowing the genetic background to be con-
trolled in future application of the in vitro model. For each individual
three iPSC clones were characterized by karyotyping and array CGH
and genomic DNAs of clones without any cytogenetic or submicroscopic
rearrangement were checked for the presence of the original mutation
by Sanger sequencing. As exempliﬁed in Suppl. Fig. 2 clone 3 from
patient #34 maintained the normal 46,XY karyotype (Suppl. Fig. 2A),
but its genomic DNA evidenced by array-CGH a rare Copy Number
Variant (CNV) at chromosome 3p14.3 (Suppl. Fig. 2B) not present in
the peripheral blood, letting to discard this clone. Clones 2 and 7 were
then checked for the presence of the original c.4435G>T pathogenic
variant (Suppl. Fig. 2C) and characterized for iPSC markers by im-
munoﬂuorescence microscopy and RT-PCR.
We scored an overall frequency of 24% rearranged iPSC clones, but
a frequency of 7% would have been detected by karyotyping alone.
Characterization of the iPSC clones included transcript and western
blot (WB) analyses. Aberrant transcripts were observed in all CREBBP-
and EP300-mutated iPSC lines though their ﬂuorescence peaks ap-
peared less represented than those encoded by the wild-type allele, with
the only exception of patient #46, carrier of a CREBBP missense mu-
tation, which aberrant transcripts were comparable to the wild-type
ones (Suppl. Fig. 3). Accordingly, Western blot analysis using anti-
bodies directed against the N-terminal portion of CBP/p300 evidenced
the expression of a full-length protein, corresponding to the wild-type
protein in reduced amount in the iPSC lines from patients with in-
activating gene mutations and in the same amount of control in #46
iPSC line (data not shown).
Valid iPSC clones entered the characterization for the pluripotency
markers Oct3/4, TRA-1-60 and Nanog by immunoﬂuorescence (IF) and
Oct3/4, SOX2 and Nanog by RT-PCR. We conﬁrmed that iPS clones
from all six RSTS patients and four controls expressed the human
pluripotency-associated gene products. Suppl. Fig. 4A shows the bright-
ﬁeld image of an iPSC colony of C1, C3, of the four CREBBP-mutated
#34, #46, #149 and #158 and of the two EP300-mutated #65 and
#207 patients and the positive expression at confocal microscopy of
Oct3/4 and TRA-1-60 in all the immunostained samples. Parallel
characterization involved RT-PCR expression analysis of Oct3/4, Sox2
and Nanog, as can be seen for four iPS clones from C1 and from #34
and #207 patients (Suppl. Fig. 4B).
3.3. From iPS colonies to neurons
Application of the monolayer protocol in N2B27 medium supple-
mented with noggin (Germain et al., 2014) induced iPS colonies from
all four controls and ﬁve RSTS patients to start and complete neuronal
diﬀerentiation. Two iPSC lines could be diﬀerentiated from patients
#34, #46, #158 and #207.
Neural diﬀerentiation is ﬁrst marked by the appearance of the ty-
pical neural rosettes (day 20) which by manual cut and culture passa-
ging are further induced to diﬀerentiate into neural progenitors (NPCs)
(day 35). At the rosette stage the majority of cells from control and
RSTS-iPSCs showed positive IF staining for the neuroectodermal stem
cell markers NESTIN and PAX6 (Fig. 1A). Foxg1, a member of the
forkhead-box family of transcription factors and Sox1, a member of the
SoxB1 family of transcriptional activators, both among the earliest
markers of neural stem cell identity, were also expressed in rosettes
from patients and controls (data not shown). NPCs self-renewed,
maintained their diﬀerentiation potential and were further induced to
diﬀerentiate into neurons. We conﬁrmed by IF that 42-day-old neurons
from both controls and all ﬁve RSTS patients expressed the neuronal
markers MAP2 (microtubule-associated protein 2) and TUJ1 (betaIII-
tubulin). Representative images are shown in Fig. 1B. We made use of
this stage at which neurons are at low density in culture to assess on
immunostained coverslips whether the morphological characteristics of
neurons diﬀered between controls and patients (see Section 3.4.)
After prolonged maintenance in culture (70 days) both control and
patient i-neurons developed a highly intricate network of cells enriched
in cortical neurons, as shown by expression of the T-Brain-1 (TBR-1)
transcription factor, a master regulator of cortical development, the cut-
like CUX-1 homeodomain transcription factor, necessary for dendrite
development of cortical neurons, and the presynaptic marker synapto-
phisyn (SYP). Representative images of TBR-1, CUX-1 and SYP-stained
coverslips from controls, CREBBP- and EP300-mutated patients are
Fig. 3. Immunoﬂuorescence characterization of excitatory and inhibitory
markers in patient-speciﬁc 70 days i-neurons. A) Positive immunostaining of
the glutamatergic subtype-speciﬁc marker vesicular neurotransmitter trans-
porter 1/2 (vGLUT1/2) and MAP2 in neurons from C3, CREBBP-mutated
#34cl2 and EP300-mutated #65. Scale bar 100 μm. B) Immunostaining of TUJ1
and the inhibitory subtype-speciﬁc marker glutamic acid decarboxylase 65/67
(GAD65/67) in neurons from the same samples shown in A). The white arrows
point to the rare GAD65/67 stained neurons. Scale bar 50 μm.
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shown in Fig. 2A–C. Both in control and patient cultures CUX-1 positive
cells were mostly concentrated in the dense clusters, and were few or
absent in culture areas close to mound or sparse (Fig. 2B). Most i-
neurons from control, CREBBP- and EP300-mutated patients were also
positive for the glutamatergic subtype-speciﬁc marker vesicular neu-
rotransmitter transporter 1/2(vGLUT1/2), while few were positive for
the glutamic-acid decarboxylase 65/67 (GAD65/67) inhibitory marker
(Fig. 3A–B)
3.4. Morphological analysis of 42 days neurons from RSTS and controls
Due to its 2D nature, the monolayer neuronal diﬀerentiation system
used enabled us to analyze cellular morphology, such as neurite length
and average number of branches on coverslips from 42-day-old neurons
from control and RSTS patients by the Plugin “Analyze Skeleton”
(Image J) (Arganda-Carreras et al., 2010).
As shown in Fig. 4 the same single cell conﬁrmed by positive im-
munostaining of MAP2 and TUJ1 to be a neuron, is elaborated as binary
image and skeletonized allowing the neurons branch length and
average number to be precisely counted. Analysis of an average of
30–50 cells from each sample, including controls (C1, C3, C4) and ﬁve
RSTS patients, three CREBBP-mutated (#34-cl 7 and cl 2-, #46 and
#158) and two EP300-mutated (#65 and #207) allowed to graph these
measures. Scores for C1, C3 and C4 were pooled together as well as
those from the two independently diﬀerentiated iPS lines from #34 as
the slight inter-culture variability was not signiﬁcant (data not shown).
The box-plots in Fig. 5A show that neurons from RSTS patients #34,
#207, #65 and #158 have an average branch length signiﬁcantly re-
duced as compared to that of controls while the values of patient #46
neurons cluster with those of controls. The box-plots in Fig. 5B evidence
a similar opposite trend for variations in the average branch number
with neurons from #46 similar to controls and those from the other
Fig. 4. Morphological analysis of 42 days neurons from patient-speciﬁc iPSCs. Positive immunostaining of MAP2 and TUJ1 conﬁrms the neuronal identity of the
diﬀerentiating single cell of C1, C4, #34cl2, #46, #158, #65 and #207. Nuclei are counterstained with DAPI. Scale Bar 50 μm. The right panels show the binary and
the skeletonized images.
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patients displaying an arborisation increasing from #34, #207 and
#158 to #65, signiﬁcantly higher than controls. The opposite trend in
neurons of RSTS patients is conﬁrmed by correlation analysis of these
two features (Fig. 5C-D): the average length and number of neuronal
branches are negatively correlated (r=−0.5, p= 1.9e−15, CI 95%:
−0.582 to−0.380) while the correlation in controls cells appear to be
consistently lower or weak (r=−0.24, p= 0.005, CI 95%: −0.414 to
−0.069).
3.5. Electrophysiology of mature cortical neurons
Neurons obtained from control (C4), CREBBP- #34, #46 and EP300-
mutated patients #65 and #207 were analyzed by patch-clamp re-
cordings after 70 days of diﬀerentiation to test their maturity and
characterize their cellular excitability. Voltage-clamp experiments
showed the expression of voltage-gated sodium and potassium currents,
similarly to mature neurons, as shown by the representative current
traces in Fig. 6A (top panels). A more detailed analysis revealed that the
majority of neurons, from both control and patients, expressed voltage-
gated sodium currents with comparable peak amplitudes (C4:
−141.4 ± 13.8 pA/pF, n=25; #34: −180.3 ± 17.7 pA/pF, n=28;
#46: −131.1 ± 22.7 pA/pF, n=13; #207: −122.6 ± 23.3 pA/pF,
n=16; #65: −151.7 ± 20.9 pA/pF, n=18; ANOVA and Bonferroni
post-test, p > 0.05). Voltage-gated potassium currents had similar
amplitude in neurons from control and patients #46, #207 and #65,
while in neurons from patient #34 they were slightly but signiﬁcantly
increased at−10, 0, +10 and +20mV with respect to control currents
(C4: 7.9 ± 1 pA/pF, 16.7 ± 1.9 pA/pF, 34.5 ± 3.6 pA/pF,
56.1 ± 5.9 pA/pF at −10, 0, +10, +20mV, respectively, n= 25;
#34: 23.2.7 ± 2.6 pA/pF, 38.7 ± 3.9 pA/pF, 59.3 ± 5.2 pA/pF,
82 ± 7 pA/pF at−10, 0, +10, +20mV, respectively, n= 28; ANOVA
and Bonferroni post-test, (p= 5.1×10−8 at−10mV, p= 5.3× 10−7
at 0mV, p= 1.1× 10−4 at +10mV, p=9.7×10−3 at +20mV)
(Fig. 6A, bottom panels). Current-clamp experiments conﬁrmed the
maturity of diﬀerentiated neurons, because they were able to generate
discharges of action potentials in response to depolarizing stimuli
(Fig. 6B, top panels). Interestingly, a lower percentage of neurons from
patients #34 and #207 produced action potentials with respect to
control ones (Fisher's exact test, p= 0.007 for pt. #34, p=0.038 for
pt. #207); moreover, neurons from all the investigated patients were
less excitable, as shown by the input-output relationships (ANOVA and
Bonferroni post-test) (Fig. 6B, bottom left and middle panels). To test
whether the observed diminished eﬃciency of patients' neurons in
generating action potentials correlated with modiﬁcations in cell ca-
pacitance, rheobase and/or AP threshold, we quantiﬁed and compared
these parameters between patients and control and disclosed an in-
creased rheobase for neurons from patients #46 (p= 7.7× 10−5) and
#207 (p= 1.8× 10−2) together with a depolarized AP threshold for
neurons from patient #207 (p=1.8×10−2), thus indicating the re-
quirement of higher stimulus intensities to reach the threshold for
generating APs (ANOVA and Bonferroni post-test) (Fig. 6B, bottom
right panel). Neurons from patient #34 did not show modiﬁcations of
these parameters, therefore their hypoexcitability may be caused by
additional mechanisms.
4. Discussion
We established the ﬁrst in vitro iPSC-derived neuronal model for
RSTS which “per se” demonstrates that the deﬁcit of CBP/p300 re-
sulting from CREBBP/EP300 haploinsuﬃciency or defective protein
function does not interfere with reprogramming and pluripotency and
does not preclude the capability of iPSC-derivatives to progress till
neurons.
As regards the ﬁrst step of the model, we could successfully repro-
gram to iPSCs blood cells from all the six selected RSTS patients and
from the four controls and carefully checked for maintenance of
genomic stability at least three iPSC clones per donor. The frequency of
rearranged iPS clones we recorded raised from 7% by karyotyping to
24% by high-resolution array-CGH. A study on comparison of non in-
tegrating reprogramming methods showed for iPSC generated by SeV
an aneuploidy rate of 4.6% by karyotyping, whereas the frequency of
CNVs by small-scale genome-wide array aCGH was said to be uniformly
low (Schlaeger et al., 2015). It is worth noting that the rate of detection
of acquired CNVs depends on the array resolution, accounting for the
high frequency of CNVs detected by our high-resolution (180-400 K)
array platform. Non random CNVs, often conferring to the carrier cells
proliferative advantage in vitro may be found in iPSC lines with normal
karyotype as shown by the chromosome 20q11.21 gain identiﬁed by
Fig. 5. Statistical analyses of morphological features
obtained from 42 days neurons of patient-speciﬁc
iPSCs. A–B) Box-plots showing the average length
(A) and number (B) distribution of neuronal bran-
ches from pooled controls (Cs) and RSTS #46, #34
(clones 2–7 pooled) #158, #207 and #65 patients.
Data are shown as median and interquartile range;
whiskers represent maximum and minimum values.
Data were acquired by using the “Analyze Skeleton”
plugin (Image J) (***p < 0.001). C–D) Scatter plots
showing the average length of neuronal branches as
function of branch number in controls (C) (121 cells)
and RSTS patients (D) (235 cells). Correlation coef-
ﬁcients (r) and p-values (p) are also shown.
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the “International Stem Cell initiative” (Amps et al., 2011) in> 20% of
human embryonic and iPSC stem lines. Our data recommend appro-
priate check of genome stability, both for correct evaluation of the
cellular phenotype of the patient iPSC-derived neurons and perspective
medical applications.
We conﬁrmed the patient-speciﬁc pathogenic variants in CREBBP
and EP300 in the iPSC lines by Sanger sequencing. Aberrant transcripts
were observed in iPSCs from all patients, though, with the exception of
#46, are featured by the respective ﬂuorescence peaks as residual
transcripts escaping non sense mediated decay. Consistent with this
data, western blot analysis did not reveal in the RSTS iPSC lines trun-
cated proteins, but haploinsuﬃciency-dependent reduction in the wild-
type CBP/p300 protein, except patient #46 showing the same quantity
of full length CBP protein of control iPSC line (data not shown).
We could obtain iPSC-neuronal cultures from all controls and three
out of four CREBBP- and two out of two EP300-mutated patients. The
fourth CREBBP-mutated patient #149 has currently progressed till the
stage of neural progenitors.
Consistent with the protocol employed to induce diﬀerentiation of
iPSCs to cortical neurons, pan neuronal (TUJ1, MAP2) and cortical-
Fig. 6. Electrophysiological characterization of neurons from control and patients after 70 days of diﬀerentiation. A) Top panels: representative total ionic currents
elicited with depolarizing voltage steps between−70 and +60mV, from a holding potential of−70mV (scale bars: 50 pA/pF, 10ms). Bottom panels: quantiﬁcation
of % of neurons with sodium current (left), sodium (middle) and potassium (right) current densities at diﬀerent potentials. Potassium current density was increased in
neurons from patient #34, which also showed a trend for increase of sodium current density. B) Top panels: representative discharges of action potentials (APs)
evoked by the injection of 2.5 s-long depolarizing stimuli at the intensity of 8–10 pA (scale bars: 20mV, 1 s). Bottom panels: quantiﬁcation of % of neurons able to
generate APs (left) and input-output relationships (middle). With respect to control neurons, a decreased percentage of neurons from patients #34 and #207
generated APs. Neurons diﬀerentiated from patients generated less APs in input-output relationships than neurons diﬀerentiated from control (statistically signiﬁcant
diﬀerences are not indicated in the graph for clarity, see text). Quantiﬁcation of cell capacitance (Cm), rheobase and AP threshold (right); rheobase was increased in
neurons from patients #46 and #207, AP threshold was depolarized in neurons from patient #207.
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speciﬁc markers (TBR-1 and CUX-1) were expressed by all patients'
neurons. It is known from mice models that Cbp regulates neural cell
genesis and cortical precursor diﬀerentiation and Cbp haploinsuﬃ-
ciency or genetic knockdown causes a small but signiﬁcant decrease in
the number of neurons generated, leaving intact proliferation and sur-
vival (Valor et al., 2011; Wang et al., 2010).
As a quantitative study to deﬁne the percentage of TUJ1-positive
cortical precursors and CUX-1 glutamatergic neurons, which are
abundant in RSTS i-neurons, could not be pursued on the numerous
RSTS and control iPSC-derivatives, based on the knowledge that mor-
phological maturation precedes functional maturation in a iPSC-derived
neuronal diﬀerentiation model (Kang et al., 2017) we evaluated mor-
phological analysis of diﬀerentiating neurons (42-days) and electro-
physiological proﬁles of diﬀerentiated neurons (> 70 days) to disclose
potential structural and functional diﬀerences between control and
patient-speciﬁc neuronal cultures.
We monitored signiﬁcant reduction in branch length and increase in
branch number with respect to control in diﬀerentiating neurons of four
out of ﬁve analyzed patients. The observed increase in branches number
is not consistent with the reported reduction in dendritic protrusions of
iPSC-neurons from other neurodevelopmental disorders (Nagy et al.,
2017; Kim et al., 2014; Linda et al., 2018). This discrepancy may be
accounted by the earlier timing of our analysis, which implies possible
spine abortion and hence decreased number in terminally diﬀerentiated
neurons. That the observed morphological alterations are patient-spe-
ciﬁc is pointed out by the similar ranking in neurons of each patient of
both evaluated parameters. As to the clustering with controls of #46, it
may reﬂect a genotype-related diﬀerence as she is the only patient
carrying a missense mutation causing a defective KAT activity not
leading to haploinsuﬃciency. A limited eﬀect of mutant Cbp proteins
carrying missense mutations in the KAT domain, including mutations
associated to RSTS, has been demonstrated on primary embryonic ﬁ-
broblasts from Cbp/p300 cre-deleted double knock-out mice that retain
signiﬁcant KAT activity, as acetylation of a known histone substrate
was attenuated, but not blocked and diﬀered between mutants
(Mullighan et al., 2011). One may speculate that the mutant CBP pro-
tein might cause impairment at a later stage of neuronal diﬀerentiation,
as inferred by the electrophysiological recordings of #46's fully diﬀer-
entiated i-neurons.
Importantly, the electrophysiological studies validate our RSTS
iPSC-derived neuronal model, because we obtained functional neurons
that could be exploited to disclose impairments in cellular excitability
of patients' neurons. These results demonstrate the maturation of iPSCs-
derivatives into functional neurons expressing sodium and potassium
currents, the principal ionic conductances involved in the generation
and propagation of action potentials. The small increase in sodium and
potassium current densities expressed by neurons from patient #34
may reﬂect the natural genetic heterogeneity that has been widely re-
ported for cell lines derived from unique individuals, rather than a
speciﬁc pathological feature (Hu et al., 2010; Adegbola et al., 2017).
The observed decreased excitability of patients' neurons may feasibly
represent one of the underlying pathological mechanisms leading to the
cognitive impairment in RSTS, as it has already been shown for iPSCs-
derived neurons of other neurodevelopmental disorders characterized
by developmental delay and intellectual disability (Marchetto et al.,
2010; Pasca et al., 2011; Mariani et al., 2015). Of interest, the elec-
trophysiological analysis of the intrinsic excitability, which is not di-
rectly linked to the morphology of neuronal branches, allowed a more
comprehensive characterization of patients' neurons. In fact, neurons of
patient #46 show intrinsic hypoexcitable features, although they are
morphologically similar to control neurons. In future studies, it will be
interesting to investigate whether the observed modiﬁcations of neu-
ronal branches lead to an altered synaptic transmission, because fea-
tures of synaptic transmission are related to dendritic and axonal
complexity.
5. Conclusions
The overall results attest that we have generated an in vitro neu-
ronal model of Rubinstein-Taybi syndrome that can be used as a robust
in vitro platform to explore the mechanistic basis of this disorder.
Morphological changes and decreased excitability of patients' neurons
are potential RSTS biomarkers to be further investigated in relation to
genotype-dependent RSTS phenotypes. The resource of i-neurons from
multiple RSTS patients can be exploited in future studies to provide
more detailed insights on correlations between the aﬀected locus, the
type of mutation and the cellular phenotype.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scr.2018.05.019.
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